Development of Rapifort<sup>Ⓡ</sup>wipes 2.5％ for the treatment of primary axillary hyperhidrosis

DOI Web Site 1 References

Bibliographic Information

Other Title
  • 原発性腋窩多汗症治療剤ラピフォート<sup>Ⓡ</sup>ワイプ2.5％の開発

Abstract

RapifortⓇwipes 2.5％is the first wipe pharmaceutical form approved in Japan and is a partially modified formulation of QbrexzaⓇdeveloped by Dermira, Inc. in January 2022. The wipe is applied to both axillae once a day to control sweating of primary axillary hyperhidrosis. The drug solution impregnated into a wipe is changed to classify it as a non-hazardous substance under the Fire Service Act in Japan. The wipe is selected for reactivity with the drug solution and water absorbency, and the pouch is designed with the multiple-layer structure to ensure drug quality. This article describes the details of the formulation change and packaging design of the wipe and the clinical trial results.

Journal

  • Drug Delivery System

    Drug Delivery System 38 (3), 246-249, 2023-07-25

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top